Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free MDNA Stock Alerts

Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics logo
C$0.39 +0.01 (+2.63%)
As of 08/6/2026 03:58 PM Eastern
Compare

MDNA vs. HBP, SCYB, COM, NVH, and PDP

Should you buy Medicenna Therapeutics stock or one of its competitors? MarketBeat compares Medicenna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medicenna Therapeutics include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and Pediapharm (PDP). These companies are all part of the "biotechnology" industry.

How does Medicenna Therapeutics compare to Helix BioPharma?

Helix BioPharma (TSE:HBP) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, Helix BioPharma's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
Medicenna Therapeutics Neutral

Helix BioPharma has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Helix BioPharma's return on equity of -21.54% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
Medicenna Therapeutics -533,640.00%-219.30%-32.80%

Helix BioPharma has a beta of 0.433836, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Medicenna Therapeutics has a beta of 2.96881, suggesting that its stock price is 197% more volatile than the broader market.

0.0% of Helix BioPharma shares are held by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by company insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Helix BioPharma is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

Summary

Medicenna Therapeutics beats Helix BioPharma on 6 of the 9 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Scythian Biosciences?

Medicenna Therapeutics (TSE:MDNA) and Scythian Biosciences (CVE:SCYB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Scythian Biosciences has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Scythian Biosciences' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -219.30% -32.80%
Scythian Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Medicenna Therapeutics' average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Scythian Biosciences Neutral

Summary

Scythian Biosciences beats Medicenna Therapeutics on 3 of the 5 factors compared between the two stocks.

How does Medicenna Therapeutics compare to 138267 (COM.TO)?

Medicenna Therapeutics (TSE:MDNA) and 138267 (COM.TO) (TSE:COM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

0.4% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Medicenna Therapeutics' average media sentiment score of 0.00 equaled 138267 (COM.TO)'saverage media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
138267 (COM.TO) Neutral

138267 (COM.TO) has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. 138267 (COM.TO)'s return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -219.30% -32.80%
138267 (COM.TO) N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
138267 (COM.TO)N/AN/AN/AN/AN/A

Summary

138267 (COM.TO) beats Medicenna Therapeutics on 3 of the 5 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Novoheart?

Novoheart (CVE:NVH) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Novoheart's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
Novoheart Neutral
Medicenna Therapeutics Neutral

Novoheart has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Novoheart's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NovoheartN/A N/A N/A
Medicenna Therapeutics -533,640.00%-219.30%-32.80%

Novoheart has higher revenue and earnings than Medicenna Therapeutics. Novoheart is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

Summary

Novoheart beats Medicenna Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Pediapharm?

Pediapharm (CVE:PDP) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

In the previous week, Pediapharm's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
Pediapharm Neutral
Medicenna Therapeutics Neutral

0.4% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pediapharm has higher revenue and earnings than Medicenna Therapeutics. Pediapharm is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PediapharmC$11.16M5.95-C$16.15M-C$0.07N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

Pediapharm has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Pediapharm's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PediapharmN/A N/A N/A
Medicenna Therapeutics -533,640.00%-219.30%-32.80%

Summary

Pediapharm beats Medicenna Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDNA vs. The Competition

Export
MetricMedicenna TherapeuticsBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$36.00MC$3.61BC$6.95BC$12.52B
Dividend YieldN/A3.77%2.59%6.20%
P/E Ratio-1.778.32270.8234.29
Price / SalesN/A1,294.25600.159.84
Price / Cash1.15101.3771.8982.29
Price / Book13.1117.6413.004.50
Net Income-C$25.98M-C$13.22MC$3.46BC$299.09M
7 Day Performance8.33%4.45%3.39%2.56%
1 Month Performance-1.27%-4.89%-2.69%1.57%
1 Year Performance-61.39%56.58%75.98%33.86%

Medicenna Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDNA
Medicenna Therapeutics
N/AC$0.39
+2.6%		N/A-60.2%C$36.00MN/AN/A20
HBP
Helix BioPharma
N/AC$1.50
flat		N/A+43.5%C$114.57MN/AN/A9
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MDNA) was last updated on 8/7/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel